Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study.
Shan LuoCatherine Mary SchoolingIan Chi Kei Ck WongShiu Lun Ryan Au YeungPublished in: Diabetologia (2020)
This study provides some genetic evidence that AMPK activation by metformin may protect against cardiovascular disease and cancer, which needs to be confirmed by randomised controlled trials.